Efekat berberina na metaboličke profile kod pacijenata sa dijabetesom tipa 2: sistematski pregled i meta-analiza randomizovanih kontrolisanih studija.
Oxidative medicine and cellular longevity
Sažetak istraživanja
Objective Rhizoma Coptidis je biljka koja se često koristi u mnogim tradicionalnim formulama za liječenje dijabetes melitusa (DM) tokom hiljada godina. Dokazano je da berberin, glavna aktivna komponenta Rhizoma Coptidis, ima potencijalni efekat hipoglikemije. Da bismo utvrdili potencijalne prednosti berberina za njegu dijabetičara, sproveli smo ovaj sistematski pregled i meta-analizu kako bismo ispitali efikasnost i sigurnost berberina u liječenju pacijenata sa DM tipa 2.
Metode Osam baza podataka uključujući PubMed, Embase, Web of Science, Cochrane biblioteku, kinesku nacionalnu infrastrukturu znanja (CNKI), kinesku biomedicinsku bazu podataka (SinoMed), Wanfang bazu podataka i kineske VIP informacije pretraženo je za randomizirana kontrolirana ispitivanja (RCT) koja izvještavaju o kliničkim podacima u vezi s upotrebom berberina za liječenje berberina. Takođe se smatralo da kvaliteti objavljivanja povećavaju kredibilitet dokaza. Glikemijski metabolizam su bili glavni proučavani faktori, uključujući glikozilirani hemoglobin (HbA1c), glukozu u plazmi natašte (FPG) i 2-satnu glukozu u krvi nakon obroka (2hPG). Inzulinska rezistencija je procijenjena inzulinom u krvi natašte (FINS), procjenom modela homeostaze-inzulinska rezistencija (HOMA-IR) i indeksom tjelesne mase (BMI). Procijenjeni su i profili lipida, uključujući trigliceride (TG), ukupni holesterol (TC), lipoproteine niske gustine (LDL) i lipoproteine visoke gustine (HDL), zajedno sa faktorima upale kao što su C-reaktivni protein (CRP), interleukin-6 (IL-6) i faktor nekroze tumora-α (αTN). Kreatinin u serumu (Scr), dušik ureje u krvi (BUN) i štetni događaji su primijenjeni za procjenu sigurnosti berberina.
Rezultati Procijenjeno je 46 ispitivanja. Analiza berberina primijenjenog samostalno ili sa standardnim terapijama za dijabetes u odnosu na kontrolnu grupu pokazala je značajno smanjenje HbA1c (MD = -0,73; 95% CI (-0,97, -0,51)), FPG (MD = -0,86, 95% CI (-1,10, -0,62%) i MD = -0,62% (MD = -0,62%) (-1,64, -0,89)). Poboljšana insulinska rezistencija je procenjena smanjenjem FINS-a (MD = -2,05, 95% CI (-2,62, -1,48)), HOMA-IR (MD = -0,71, 95% CI (-1,03, -0,39)) i BMI (MD = -1,07, 15,76 % CI) (-0,76%). Metabolizam lipida je također poboljšan smanjenjem TG (MD = -0,5, 95% CI (-0,61, -0,39)), TC (MD = 0,64, 95% CI (-0,78, -0,49)) i LDL (MD = 0,86, 95% CI, regulacija -15% CI, -0,65) HDL (MD = 0,17, 95% CI (0,09, 0,25)). Uz to, berberin je poboljšao faktor upale.
Zaključak Postoje jaki dokazi koji podržavaju kliničku efikasnost i sigurnost berberina u liječenju DM, posebno kao pomoćne terapije. U budućnosti, ovo bi se moglo koristiti za usmjeravanje ciljane kliničke upotrebe berberina i razvoja lijekova za liječenje pacijenata sa T2DM i dislipidemijom.
Prikaži originalni naslov i sažetak na engleskom
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Objective Rhizoma Coptidis is an herb that has been frequently used in many traditional formulas for the treatment of diabetic mellitus (DM) over thousands of years. Berberine, the main active component of Rhizoma Coptidis , has been demonstrated to have the potential effect of hypoglycemia. To determine the potential advantages of berberine for diabetic care, we conducted this systematic review and meta-analysis to examine the efficacy and safety of berberine in the treatment of patients with type 2 DM.
Methods Eight databases including PubMed, Embase, Web of Science, the Cochrane library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Database (SinoMed), Wanfang Database, and Chinese VIP Information was searched for randomized controlled trials (RCTs) reporting clinical data regarding the use of berberine for the treatment of DM. Publication qualities were also considered to augment the credibility of the evidence. Glycemic metabolisms were the main factors studied, including glycosylated hemoglobin (HbA1c), fasting plasm glucose (FPG), and 2-hour postprandial blood glucose (2hPG). Insulin resistance was estimated by fasting blood insulin (FINS), homeostasis model assessment-insulin resistance (HOMA-IR), and body mass index (BMI). Lipid profiles were also assessed, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein (HDL), along with inflammation factors such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor- α (TNF- α ). Serum creatinine (Scr), blood urea nitrogen (BUN), and adverse events were applied to evaluate the safety of berberine.
Results Forty-six trials were assessed. Analysis of berberine applied alone or with standard diabetic therapies versus the control group revealed significant reductions in HbA1c (MD = -0.73; 95% CI (-0.97, -0.51)), FPG (MD = -0.86, 95% CI (-1.10, -0.62)), and 2hPG (MD = -1.26, 95% CI (-1.64, -0.89)). Improved insulin resistance was assessed by lowering FINS (MD = -2.05, 95% CI (-2.62, -1.48)), HOMA-IR (MD = -0.71, 95% CI (-1.03, -0.39)), and BMI (MD = -1.07, 95% CI (-1.76, -0.37)). Lipid metabolisms were also ameliorated via the reduction of TG (MD = -0.5, 95% CI (-0.61, -0.39)), TC (MD = 0.64, 95% CI (-0.78, -0.49)), and LDL (MD = 0.86, 95% CI (-1.06, -0.65)) and the upregulation of HDL (MD = 0.17, 95% CI (0.09, 0.25)). Additionally, berberine improved the inflammation factor.
Conclusion There is strong evidence supporting the clinical efficacy and safety of berberine in the treatment of DM, especially as an adjunctive therapy. In the future, this may be used to guide targeted clinical use of berberine and the development of medications seeking to treat patients with T2DM and dyslipidemia.
Izvorni podaci
- DOI
- 10.1155/2021/2074610
- PMID
- 34956436
- PMCID
- PMC8696197
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom